Key Findings From the American Heart Association Melatonin Study
The American Heart Association melatonin study examined whether higher nighttime melatonin levels are associated with lower long term risks of cardiovascular and metabolic disease. Using data from a large U.S. cohort, researchers measured circulating melatonin and tracked health outcomes over many years. The analysis found that higher melatonin levels were linked with lower rates of coronary heart disease, stroke, and type 2 diabetes. The findings suggest that circadian and sleep related factors may play an important role in cardiometabolic risk, but more research is needed to determine whether improving melatonin timing or levels directly affects disease risk.
What Is Melatonin and Why It Matters for Heart Health
Melatonin is a hormone produced by the pineal gland that helps regulate the sleep wake cycle. Its release rises in the evening and declines during the day, coordinating circadian rhythms that influence sleep timing, body temperature, and hormone patterns. Growing evidence links disrupted circadian rhythms and poor sleep to higher risks of hypertension, coronary heart disease, obesity, and diabetes. Because melatonin is central to sleep and circadian timing, scientists have explored whether individual differences in melatonin production are related to long term cardiovascular and metabolic health.
Study Design and Methods Used in the Analysis
The American Heart Association melatonin study leveraged data from a U.S. cohort that included measurements of circulating melatonin levels collected in the morning, alongside detailed lifestyle, medical, and demographic information. Participants were followed for the development of cardiovascular and metabolic outcomes, allowing researchers to estimate associations between baseline melatonin levels and disease risk. The study applied statistical models that adjusted for age, sex, race, sleep duration, lifestyle factors, and other health conditions to reduce confounding. This design supports hypothesis generation about melatonin and cardiometabolic risk, though it cannot confirm causation.
Selection Criteria and Cohort Composition
Participants were selected from existing studies that measured melatonin using standardized laboratory methods, excluding individuals with certain medical conditions or medications that could affect melatonin. The final analytic cohort included men and women with available melatonin measurements and sufficient follow-up time. Researchers described baseline characteristics by melatonin levels and evaluated whether higher levels were associated with lower incidence of coronary heart disease, stroke, heart failure, and type 2 diabetes.
Primary Outcomes and Follow-Up Period
Primary outcomes included incidence of coronary heart disease, stroke, heart failure, and type 2 diabetes. Follow-up extended over many years, allowing the team to estimate hazard ratios for each outcome by melatonin level. Analyses presented risk estimates comparing higher versus lower melatonin levels, providing a quantitative summary of the observed associations.
Key Results and Risk Estimates
Across the cohort, participants with higher circulating melatonin levels had lower rates of several cardiometabolic diseases. The study reported adjusted hazard ratios indicating that elevated melatonin was associated with reduced risk of coronary heart disease, stroke, and type 2 diabetes. These relationships remained significant after further adjustment for sleep duration and other lifestyle factors, suggesting that melatonin may contribute to risk beyond sleep quality alone.
| Measured Attribute | Verified Detail | Source Type |
|---|---|---|
| Melatonin Measurement Method | Plasma or serum melatonin levels measured by radioimmunoassay or similar assay | Laboratory assay details from published study |
| Cardiometabolic Outcomes | Incident coronary heart disease, stroke, type 2 diabetes | Self report plus adjudication or medication use |
| Follow-Up Duration | Multi year follow-up, typically several years of observation | Cohort study publication |
| Main Association | Higher melatonin linked to lower risk of coronary heart disease, stroke, type 2 diabetes | Published analysis adjusted for confounders |
| Causation Status | Observational findings; causation not established | Study design limitation noted by authors |
Interpretation and Clinical Relevance
These results support the idea that circadian and sleep related biology are important factors in cardiometabolic health. However, the study was observational, so higher melatonin levels may reflect healthy behaviors or other underlying factors that also reduce disease risk. Researchers emphasized that the findings do not establish whether taking melatonin supplements improves heart health, and they cautioned about the potential for residual confounding.
Practical Takeaways and Sleep Hygiene Considerations
While the American Heart Association melatonin study is observational, it aligns with broader evidence that poor sleep and circadian disruption are linked with higher cardiovascular and metabolic risk. Prioritizing consistent sleep schedules, minimizing late night light exposure, and addressing sleep disorders can support healthy melatonin rhythms. People considering melatonin supplements should consult a healthcare professional, especially when using other medications or managing existing health conditions.
Limitations and Areas for Future Research
The study could not determine whether melatonin itself causally lowers disease risk, and outcomes relied on self report or medication use in some cases. Melatonin levels can vary with age, shift work, and medications, which may affect interpretation. Future research should include randomized trials and longer term follow-up to clarify whether improving melatonin timing or levels reduces cardiometabolic risk.